Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine + propofol + nalbuphine vs propofol + nalbuphine for painless gastrointestinal endoscopy
ChiCTR2500108720Phase 4Not yet recruiting
- Sponsor
- Beijing Miyun District Hospital
- Start
- Sep 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in gastroesophageal reflux disease (GERD), gastritis, gastric ulcer and 2 more comparing Dexmedetomidine + propofol + nalbuphine with Propofol + nalbuphine (2 arms). Primary endpoint: Incidence of endoscope insertion reactions during gastroenteroscopy. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
dexmedetomidinepropofolnalbuphine
03
Conditions
gastroesophageal reflux disease (GERD)gastritisgastric ulcergastric cancer (GC)Digestive tract dysfunction
Beyond the preview
Go deeper on ChiCTR2500108720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108720.